Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Longitudinal linear-epitope profiling of SLE identifies novel antigens associated with disease and disease activity. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmra1100359
10.1056/nejmra1100359 · External reference
2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus
10.1002/art.40930 · 2019 · External reference
10.1111/j.1365-3083.2012.02728.x
10.1111/j.1365-3083.2012.02728.x · External reference
10.1056/nejmoa2001180
10.1056/nejmoa2001180 · External reference
10.1136/annrheumdis-2011-200831
10.1136/annrheumdis-2011-200831 · External reference
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
10.1002/art.40049 · 2017 · External reference
Unresolved reference
External reference
10.1056/nejmoa2410965
10.1056/nejmoa2410965 · External reference
10.1056/nejmoa2308917
10.1056/nejmoa2308917 · External reference
10.1038/s41591-022-02017-5
10.1038/s41591-022-02017-5 · External reference
10.1038/s41591-025-04185-6
10.1038/s41591-025-04185-6 · External reference
10.1186/s13045-026-01779-6
10.1186/s13045-026-01779-6 · External reference
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
10.1038/s41591-025-03937-8 · 2025 · External reference
10.1016/s0065-2776(08)60836-6
10.1016/s0065-2776(08)60836-6 · External reference
10.1073/pnas.76.11.5495
10.1073/pnas.76.11.5495 · External reference
10.1038/nm0302-295
10.1038/nm0302-295 · External reference
10.7554/elife.55053
10.7554/elife.55053 · External reference
10.3389/fimmu.2020.623944
10.3389/fimmu.2020.623944 · External reference
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus
10.1126/scitranslmed.ady0210 · 2025 · External reference
10.1126/science.abj8222
10.1126/science.abj8222 · External reference
10.1038/s41586-022-04432-7
10.1038/s41586-022-04432-7 · External reference
10.1172/jci200523661
10.1172/jci200523661 · External reference
10.1038/s41591-024-02938-3
10.1038/s41591-024-02938-3 · External reference
10.1016/j.jaut.2013.01.013
10.1016/j.jaut.2013.01.013 · External reference
CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis
10.1126/scitranslmed.adz6566 · 2026 · External reference
10.1212/nxi.0000000000200551
10.1212/nxi.0000000000200551 · External reference
10.1038/nbt.1856
10.1038/nbt.1856 · External reference
Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients
10.1172/jci.insight.169515 · 2023 · External reference
10.1038/s41586-024-07722-4
10.1038/s41586-024-07722-4 · External reference
Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq
10.7554/elife.78550 · 2022 · External reference
10.1101/2023.06.12.23291297
10.1101/2023.06.12.23291297 · External reference
10.1172/jci180012
10.1172/jci180012 · External reference
10.1080/08916934.2019.1581774
10.1080/08916934.2019.1581774 · External reference
Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects
2014 · External reference
10.1016/j.cell.2012.04.031
10.1016/j.cell.2012.04.031 · External reference
10.1016/j.cell.2023.12.037
10.1016/j.cell.2023.12.037 · External reference
10.1186/s12943-020-1146-4
10.1186/s12943-020-1146-4 · External reference
10.1038/nrrheum.2015.151
10.1038/nrrheum.2015.151 · External reference
10.1093/nar/gkv416
10.1093/nar/gkv416 · External reference
10.1038/s41594-021-00601-w
10.1038/s41594-021-00601-w · External reference
10.1126/sciadv.aax5349
10.1126/sciadv.aax5349 · External reference
10.1038/s41467-024-55089-x
10.1038/s41467-024-55089-x · External reference
10.3389/fimmu.2025.1731285
10.3389/fimmu.2025.1731285 · External reference
10.1056/nejmoa021933
10.1056/nejmoa021933 · External reference
10.1074/jbc.ra118.001747
10.1074/jbc.ra118.001747 · External reference
The Diagnostic Value of Soluble Epstein-Barr Virus BZLF1 Protein in Posttransplant Lymphoproliferative Disease Among Solid Organ and Hematopoietic Cell Transplant Recipients
10.1093/infdis/jiaf477 · 2026 · External reference
10.1172/jci119856
10.1172/jci119856 · External reference
10.4049/jimmunol.174.11.6599
10.4049/jimmunol.174.11.6599 · External reference
10.1038/nm1167
10.1038/nm1167 · External reference
Population-scale sequencing resolves determinants of persistent EBV DNA
10.1038/s41586-025-10020-2 · 2026 · External reference
10.1128/jvi.00154-07
10.1128/jvi.00154-07 · External reference
10.3390/v9110341
10.3390/v9110341 · External reference
Epstein–Barr virus pathogenesis and emerging control strategies
10.1038/s41579-025-01181-y · 2025 · External reference
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study
10.1002/art.38790 · 2014 · External reference
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
10.1002/art.41466 · 2021 · External reference
10.17504/protocols.io.4r3l229qxl1y/v1
10.17504/protocols.io.4r3l229qxl1y/v1 · External reference
10.1016/j.cell.2018.11.004
10.1016/j.cell.2018.11.004 · External reference
The relationship between disease activity and expert physician’s decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials
1998 · External reference
10.1136/annrheumdis-2018-214502
10.1136/annrheumdis-2018-214502 · External reference
Unresolved reference
External reference
10.1172/jci.insight.174976
10.1172/jci.insight.174976 · External reference
